DEVELOPMENT OF A NEW QUARTERLY RISPERIDONE FORMULATION (Q3178153): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available., remove_old_engli...) |
(Created claim: summary (P836): The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available., translated_summary) |
||||||||||||||
| Property / summary | |||||||||||||||
The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available. (English) | |||||||||||||||
| Property / summary: The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 18:56, 12 October 2021
Project Q3178153 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A NEW QUARTERLY RISPERIDONE FORMULATION |
Project Q3178153 in Spain |
Statements
1,280,906.4 Euro
0 references
1,601,133.0 Euro
0 references
80.0 percent
0 references
18 November 2019
0 references
30 September 2021
0 references
LABORATORIOS FARMACEUTICOS ROVI, S.A.
0 references
37°8'35.23"N, 3°37'39.83"W
0 references
18021
0 references
El objetivo del proyecto es desarrollar una formulación de Risperidona Trimestral ISM con el grado de funcionalidad adecuado y elevada viabilidad para su futura fabricación que permitan ofrecer un producto de calidad como alternativa a las formulaciones depot de risperidona disponibles hasta el momento, así como a la ya desarrollada con esta tecnología, pero con una liberación prolongada de duración 3 veces superior a las actualmente disponibles. (Spanish)
0 references
The aim of the project is to develop a formulation of Risperidone Quarterly ISM with the appropriate degree of functionality and high feasibility for its future manufacture that allows to offer a quality product as an alternative to the depot formulations of risperidone available so far, as well as to the one already developed with this technology, but with a prolonged release of 3 times longer than those currently available. (English)
12 October 2021
0 references
Armilla
0 references
Identifiers
IDI-20200346
0 references